Associations Between Circulating Metabolites and Skin Cancer: A Bidirectional Two-Sample Mendelian Randomization Study.
- 1Department of Dermatology, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China.
- 2Hunan Key Laboratory of Medical Epigenetics, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China.
Abstract
Background
Skin cancer is the most common type of cancer worldwide, categorized into melanoma and non-melanoma types. While genetics play a crucial role in the development of skin cancer, recent developments in metabolomics have revealed that circulating metabolites influence genetic risk profiles.Methods
In this study, we utilized a bidirectional two-sample Mendelian Randomization (MR) approach, analyzing metabolite datasets from the Canadian Longitudinal Study of Aging (CLSA) and skin cancer datasets from the UK Biobank. Replication analyses were performed with the 10th round of the FinnGen project. Instrumental variables (IVs) were chosen according to established MR criteria and assessed through the Wald ratio, IVW, MR-Egger, and weighted median methods. Various sensitivity analyses were conducted utilizing Cochrane's Q, Egger's intercept, MR-PRESSO, and leave-one-out (LOO) techniques.Results
After meticulous analysis, we identified causal relationships between circulating metabolites and skin cancer risks. Specifically, levels of 1,2-dilinoleoyl-GPE (18:2/18:2), 1-palmitoyl-2-linoleoyl-gpc (16:0/18:2), 1-stearoyl-2-arachidonoyl-gpc (18:0/20:4), 1-stearoyl-2-linoleoyl-gpc (18:0/18:2), and Docosapentaenoate n3 DPA, the ratio of Arachidonate (20:4n6) to oleate to vaccenate (18:1), and Oleoyl-linoleoyl-glycerol (18:1 to 18:2) to linoleoyl-arachidonoyl-glycerol (18:2 to 20:4) were linked to non-melanoma skin cancer, whereas levels of trans-urocanate were causally linked to melanoma of skin, and S-adenosylhomocysteine (SAH) showed a putative association. It should be noted that docosapentaenoate n3 DPA and SAH were each supported by a single SNP and should be interpreted as hypothesis-generating rather than definitive causal evidence. Reverse MR analysis highlighted robust causal relationships with 18 and 10 metabolites and non-melanoma skin cancer and melanoma of skin, respectively.Conclusion
These findings enhance our understanding of skin cancer etiology and risk factors, providing genetic evidence for hypothesis-generating associations that support the development of targeted therapies and aid in the identification of potential biomarkers.
Related
- Causal associations between gut microbiota and autism spectrum disorder and attention-deficit/hyperactivity disorder: a two-sample mendelian randomization study
- Genetic associations in the gut–lung axis: a Mendelian randomization study and in vitro assessment of sodium butyrate in non-small cell lung cancer
- Exploring the relationship between gut microbiota and pan-cancer: a meta-analysis of Mendelian randomization studies
- Circulating arginine–nitric oxide pathway metabolites and nitrated fatty acids in relation to pathological features of colorectal cancer
- Single-Cell and Mendelian Randomization Analyses Reveal Novel Genetic Risk Genes of Perivascular Macrophages in Parkinson’s Disease
BibTeX
@article{yu2026associations,
title = {{Associations Between Circulating Metabolites and Skin Cancer: A Bidirectional Two-Sample Mendelian Randomization Study.}},
author = {Jiangfan Yu and Hongyan Gong and Zhuotong Zeng and Rong Xiao},
journal = {Cancer medicine},
year = {2026},
month = oct,
doi = {10.1002/cam4.72313},
url = {https://europepmc.org/article/MED/42897093},
note = {CC BY-NC-ND},
}
RIS
TY - JOUR
TI - Associations Between Circulating Metabolites and Skin Cancer: A Bidirectional Two-Sample Mendelian Randomization Study.
AU - Jiangfan Yu
AU - Hongyan Gong
AU - Zhuotong Zeng
AU - Rong Xiao
PY - 2026
DA - 2026/10/01
JO - Cancer medicine
DO - 10.1002/cam4.72313
UR - https://europepmc.org/article/MED/42897093
AB - Background Skin cancer is the most common type of cancer worldwide, categorized into melanoma and non-melanoma types. While genetics play a crucial role in the development of skin cancer, recent developments in metabolomics have revealed that circulating metabolites influence genetic risk profiles.Methods In this study, we utilized a bidirectional two-sample Mendelian Randomization (MR) approach, analyzing metabolite datasets from the Canadian Longitudinal Study of Aging (CLSA) and skin cancer datasets from the UK Biobank. Replication analyses were performed with the 10th round of the FinnGen project. Instrumental variables (IVs) were chosen according to established MR criteria and assessed through the Wald ratio, IVW, MR-Egger, and weighted median methods. Various sensitivity analyses were conducted utilizing Cochrane's Q, Egger's intercept, MR-PRESSO, and leave-one-out (LOO) techniques.Results After meticulous analysis, we identified causal relationships between circulating metabolites and skin cancer risks. Specifically, levels of 1,2-dilinoleoyl-GPE (18:2/18:2), 1-palmitoyl-2-linoleoyl-gpc (16:0/18:2), 1-stearoyl-2-arachidonoyl-gpc (18:0/20:4), 1-stearoyl-2-linoleoyl-gpc (18:0/18:2), and Docosapentaenoate n3 DPA, the ratio of Arachidonate (20:4n6) to oleate to vaccenate (18:1), and Oleoyl-linoleoyl-glycerol (18:1 to 18:2) to linoleoyl-arachidonoyl-glycerol (18:2 to 20:4) were linked to non-melanoma skin cancer, whereas levels of trans-urocanate were causally linked to melanoma of skin, and S-adenosylhomocysteine (SAH) showed a putative association. It should be noted that docosapentaenoate n3 DPA and SAH were each supported by a single SNP and should be interpreted as hypothesis-generating rather than definitive causal evidence. Reverse MR analysis highlighted robust causal relationships with 18 and 10 metabolites and non-melanoma skin cancer and melanoma of skin, respectively.Conclusion These findings enhance our understanding of skin cancer etiology and risk factors, providing genetic evidence for hypothesis-generating associations that support the development of targeted therapies and aid in the identification of potential biomarkers.
SN - 2045-7634
ER -